Abstract

 CADTH recommends that Orladeyo be reimbursed by public drug plans for routine prevention of attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years of age and older, if certain conditions are met.
 Orladeyo should only be reimbursed for adults and adolescents with HAE according to the criteria used by public drug plans for lanadelumab for the prevention of HAE attacks.
 In addition to following pre-existing criteria for lanadelumab, Orladeyo should not be used in combination with other medications for long-term prevention of angioedema. Orladeyo should only be reimbursed if its cost is reduced.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
